Vincent Rajkumar: CHMP Recommends Approval of New DARZALEX Indication for Smouldering Multiple Myeloma
Vincent Rajkumar, Professor of Medicine at the Mayo Clinic in Rochester, Minnesota, and Chair for the Mayo Clinic, shared a post on X:
“Breaking: Big news for smoldering myeloma.
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the approval of a new indication for DARZALEX(daratumumab) subcutaneous (SC) formulation as monotherapy for the treatment of adult patients with smouldering multiple myeloma (SMM) at high-risk of developing multiple myeloma.
This is based on results of the AQUILA trial.
If approved, patients with high risk smoldering myeloma will have a choice that can delay progression to active myeloma and highly likely to prolong life.
More posts featuring Vincent Rajkumar.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023